Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-09-15
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546199, 546201, 514322, A01N 4340
Patent
active
058078711
ABSTRACT:
Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.
REFERENCES:
patent: 2891066 (1959-06-01), Parcell
patent: 3135794 (1964-06-01), Archer
patent: 3408356 (1968-10-01), Horovitz
patent: 3476760 (1969-11-01), Kaiser et al.
patent: 3558637 (1971-01-01), Kaiser et al.
patent: 3686186 (1972-08-01), Houlihan et al.
patent: 3745165 (1973-07-01), Houlihan et al.
patent: 3962259 (1976-06-01), Bauer et al.
patent: 3980658 (1976-09-01), Possanza et al.
patent: 3985889 (1976-10-01), Bauer et al.
patent: 3993764 (1976-11-01), Dumont et al.
patent: 3996211 (1976-12-01), Lassen
patent: 4038395 (1977-07-01), Lassen
patent: 4139634 (1979-02-01), Pigerol et al.
patent: 4166119 (1979-08-01), Effland et al.
patent: 4196209 (1980-04-01), Dumont et al.
patent: 4208417 (1980-06-01), Uzan et al.
patent: 4251538 (1981-02-01), Hausberg et al.
patent: 4333939 (1982-06-01), Guillaume et al.
patent: 4358456 (1982-11-01), Ward
patent: 4420485 (1983-12-01), Davis et al.
patent: 4443448 (1984-04-01), B.o slashed.ges.o slashed. 424250
Adachi et al. (1985), "Aminohaloborane in Organic Synthesis. IX. .sup.1) Exlcusive Ortho Acylation Reaction of N-Monoaminoalklani-lines", Chem. Pharm. Bull., vol. 33(5), pp. 1826-1835.
Arnt, J. et al. (1989), "In Vivo Pharmacology of Irindalone, a 5-HT.sub.2 Receptor Atanagonist With Predominant Peripheral Effects", Drug Develop. Res., vol. 16, pp. 59-70.
Barry et al. (1987), "Withdrawal Syndrome Following Subchronic Treatment with Anxiolytic Agents", Pharmac. Biochem. Behav., vol. 27, pp. 239-245.
B.o slashed.ges.o slashed., K. P. et al. (1993), "Stereospecific and Selective 5-HT.sub.2 Antagonism in a Series of 5-Substituted trans-1-Piperazino-3-Phenylindans", J. Med. Chem., vol. 36, pp. 2761-2770.
B.o slashed.ges.o slashed., K. P. et al. (1985), "3-Phenyl-1-indanamines. Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake", J. Med. Chem., vol. 28, pp. 1817-1828.
B.o slashed.ges.o slashed., K. P. et al. (1988), "Antihypertensive Activity in a Series of 1-Piperazino-3-phenylindans with Potent 5-HT.sub.2 -Antagonostic Activity", J. Med. Chem., vol. 31, pp. 2247-2256.
B.o slashed.ges.o slashed., K. P. (1983), "Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans", J. Med. Chem., vol. 26, pp. 935-947.
Casini, G. et al. (1969), "On 1,2-Benzisoxazole-3-acetic Acid and 3-Methyl-1,2-Bennzisoxazloe: A Restatement", J. Het. Chem., vol. 6, pp. 279-283.
Gladstone et al. (1965), J. Chem. Soc., vol. 7, 3048.
Greuter et al. (1974), Helv. Chem. Acta, vol. 57, p. 281.
Hino, T. et al. (1974), "Bromination of 3-Phenylindoles", Tetrahedron, vol. 30, pp. 2123-2133.
Hughes, G. K. et al. (1939), "Researchers of Indoles", J. Proc. Roy. Soc. N.S. Wales, vol. 72, pp. 209-221.
Hyttel, J. et al. (1985), "Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin", J. Neurochem., vol. 44, pp. 1615-1622.
Hyttel, J. et al. (1988), "Neurochemical Profile In Vitro of Irindalone: A 5-HT.sub.2 -Receptor Antagonisit", Drug Dev. Res., vol. 15, pp. 389-404.
Jones, C.D. (1972), J. Org. Chem., vol. 37, p. 3624.
LeFur, G. et al. (1977), "Effects of 4-(3-Indolyl-Alkyl) Piperidine Derivatives on Uptake and Release of Noradrenaline, Dopamine and 5-Hydroxytryptamine in Rat Brain Synaptosomes, Rat Heart and Human Blood Platelets", Biochem. Pharmacol., vol. 26, pp. 497-503.
Martin et al. (1989), "Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy", J. Med. Chem., vol. 32, pp. 1052-1056.
Mays, R. P. et al. (1980), "Synthesis of 2-Amino-3-Benzoylphenylacetic Acid", J. Heterocyclic Chem., vol. 17, No. 8, pp. 1663-1664.
McElvain, S. M. et al. (1950), "Piperidine Derivatives. XXIII. Certain Halogenated 1-Methyl-4-Phenylpiperidines and Related Compounds", J. Amer. Chem. Soc., vol. 72, pp. 3134-3138.
McMillen, B. A. et al. (1988), "N-Alkyl-Substituted Aryl-Piperazine Drugs: Relationship Between Affinity for Serotonin Receptors and Inhibition of Aggression", Drug Develop. Res., vol. 12, pp. 53-62.
Morooka, S. et al. (1978), "A Convenient Synthesis of 2-Cyano-3-Phenylindoles", Synthesis, No. 6, pp. 445 & 446.
Schulenberg, J. W. et al. (1965), "The Chapman Rearrangement", Organic Reactors, vol. 14, pp. 1-51.
Perregaard, J. et al. (1992), "Noncataleptogenic, Centrally Acting Dopamien D-2 and Serotonin 5-HT.sub.2 Antagonists within A Series of 3-Substituted 1-(4-Fluorophenyl)-1H-indoles", J. Med. Chem., vol. 35, pp. 1092-1101.
Rao, T. S. et al. (1990), "Inhibition of Climbing and Mossy Fiber, and Basket and Stellate Cell Inputs to Mouse Cerebellar Purkinje Cells by Novel Anti-Ischemic Agents, Ifenprodil and BMY-14802", Life Sciences, vol. 47, pp. PL-1-PL-5.
Rosenzweig-Lipson, S. et al. (1992), "Stereoselectic Behavorial Effects of Lu 19-005 in Monkeys: Relation to Binding at Cocaine Recognition Sites", Psychopharmacology, vol. 107, pp. 186-194.
Sanchez et al. (1991), "Neurochemical and In Vitro Pharmacological Profile of Sertindole, a Limbic-Selective Neuroleptic Compound", Drug Deve. Res., vol. 22, pp. 239-250.
Skarsfeldt, T. et al. (1990), "Sertindole, A New Neuroleptic with Extreme Selectivity on A10 Versus A9 Dopamine Neurones in the Rat", Eur. J. Pharmacol., vol. 182, pp. 613-614.
Szabo-Pusztay et al. (1979), "A Simple General Method for the Oxidation of Indoles to Oxindoles", Synthesis, vol. 86, pp. 276-277.
Ueda et al., "Preparation of Piperidinoalkyl Thiazoles as Antiallergic Agents", Chemical Abstract, vol. 107, Abstract No. 236692F (1987).
Yamamoto, H. et al. (1968), "I-Acylindoles. VII..sup.1) On Formation Reaction of Indoles from Phenylhydrazines with Several Acidic Catalysts", Chem. Pharm. Bull., vol. 16, No. 12, pp. 2313-2319.
Rao, Tadimeti S. et al. (1990), "BMY-14802 Antagonizes Harmaline-and D-Serine-Induced Increases in Mouse Cerebellar Cyclic GMP: Neurochemical Evidence for a .sigma. Receptor-Mediated Functional Modulation of Responses Mediated by the N-Methyl-D-aspartate Receptor Complex In Vivo", Molecular Pharmacology, vol. 37, pp. 978-982. 4'-piperidines! as Potential Central Nervous System Agents. 4. Central Nervous System Depressants", J. Med. Chem., vol. 21, No. 11, pp. 1149-1154.
Chambers, M. S. et al. (1992), "Spiropiperidines as High-Affinity, Selective .alpha. Ligands", J. Med. Chem., vol. 35, pp. 2033-2039.
Marxer et al. (1975), "Spiro Piperidines. I. Synthesis of 3'-piperidines!", J. Org. Chem., vol. 40, No. 10, pp. 1427-1433.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Chem. Pharm. Bull., vol. 29, No. 12, pp. 3494-3498.
Yamato, M. et al. (1981), "Synthesis and Structure-Activity Relationship of Release", J. Med. Chem., vol. 24, pp. 194-198.
Martin, PT et al. (1994), "Efficacy and Safety of Sertindole in Two Double-Blind, Placebo-Blind, Placebo-Controlled Trials of Schizophrenic Patients", Schizophrenia Research, vol. 11, p. 107.
Snyder, S.H. et al. (1989), "Receptor Mechanisms in Antipsychotic Drug Action: Focus on Sigma Receptors," Neuropsychiatry, v
Moltzen Ejner K.
Perregaard Jens Kristian
Dahlen Garth M.
H. Lundbeck A/S
Ivy C. Warren
LandOfFree
Piperidine derivatives having anxiolytic effect does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives having anxiolytic effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives having anxiolytic effect will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-87732